세계의 맥락막 신생혈관 시장 보고서(2025년)

Choroidal Neovascularization Global Market Report 2025

US $ 4,490 ￦ 6,319,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,134,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,949,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

맥락막 신생혈관 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.7%로 성장할 전망이며, 56억 4,000만 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 환자 의식 고조, 광코히렌스트모그래피 혈관조영 채용 확대, 저침습 수술 수요 증가, 유리한 상환 정책, 노인 인구 증가 등의 요인에 의한 것입니다. 이 시기 주요 동향으로는 유리체 내 항혈관내피증식인자(VEGF) 요법 출현, 새로운 유전자 치료, 유전자 치료 접근법, 원격의료 채택, 병용요법 개발, 개별화 치료 전략 등이 있습니다.

노화 황반 변성증(AMD)의 유병률 증가가 향후 맥락막 신생혈관(CNV) 시장의 성장을 견인할 것으로 예상되고 있습니다. AMD는 황반이 서서히 손상되면서 특히 노인들의 중심 시력이 저하되는 눈 질환입니다. AMD의 유병률 상승은 인구의 고령화, 평균 수명의 연장, 라이프 스타일의 변화, 유전적 영향, 환경 위험에 대한 노출 증가 등의 요인에 의한 것입니다. CNV는 망막 아래에서 혈관이 비정상적으로 증식해 시력이 저하되는 습성 AMD에서 중요한 역할을 하고 있습니다. CNV를 관리하여 AMD의 진행을 늦추고 이환자의 중심 시력을 유지하기 위해 항VEGF요법 등 선진 치료가 이루어지고 있습니다. 예를 들어 2022년 9월 미국 국립위생연구소는 2040년까지 AMD 환자가 3억 명에 달하고 2050년까지 540만 명의 미국인이 이환될 수 있다고 예측했습니다. 따라서 AMD의 유병률 상승이 CNV 시장의 성장을 촉진하고 있습니다.

CNV 시장의 주요 기업은 광선역학적 요법(PDT)과 같은 혁신적인 치료법의 개발에 주력하고 있으며, 안과 의료 전문가에게 환자의 결과와 치료 효과를 높이는 보다 정확하고 효과적인 선택을 제공합니다. PDT는 빛에 의해 활성화되는 광증감제를 사용하여 이상세포나 암세포를 표적으로 하여 파괴합니다. 예를 들면, 2023년 2월, 캐나다를 거점으로 하는 헬스케어 기업 보쉬롬과 핀란드를 거점으로 하는 바이오 메디컬 기업 Modulight사는, 미국 식품의약국으로부터 광선 역학적 레이저 ML6710i가 승인되었다고 발표했습니다. 이 치료법은 보쉬롬의 VISUDYNE 요법과 병용되어 AMD에 의한 CNV를 치료합니다. 이 선진적인 이동식 안과용 레이저는 눈 내의 비정상적인 혈관을 치료하기 위한 표적을 좁힌 접근법을 제공하여 질병의 추가적인 진행을 막고 시력을 유지하는 데 도움이 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 맥락막 신생혈관 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 맥락막 신생혈관 시장 : 성장률 분석
• 세계의 맥락막 신생혈관 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 맥락막 신생혈관 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 맥락막 신생혈관 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 맥락막 신생혈관 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 항혈관 신생요법
• 레이저광 응고술
• 광선역학요법
• 벨테포르핀 나트륨
• 라니비주맙
• 베바시주맙
• 아프리베르셉트
• 페가 타니브 나트륨
• 세계의 맥락막 신생혈관 시장 : 적응증별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 노화황반변성(AMD)
• 당뇨병 황반부종(DME)
• 중심성 장액성 맥락망막증(CSC)
• 폴립형 맥락막 혈관증(PCV)
• 근시성 황반변성(MMD)
• 기타 적응증
• 세계의 맥락막 신생혈관 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 유리체내
• 결막하
• 눈 주위
• 오랄
• 세계의 맥락막 신생혈관 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 안과 클리닉
• 외래수술센터(ASC)
• 연구센터
• 세계의 맥락막 신생혈관 시장 : 항혈관 신생요법(항 VEGF 요법) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 라니비주맙
• 베바시주맙
• 아프리베르셉트
• 페가 타니브 나트륨
• 세계의 맥락막 신생혈관 시장 : 레이저 광응고술 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 열 레이저 광응고술
• 마이크로 펄스 레이저 요법
• 세계의 맥락막 신생혈관 시장 : 광선역학요법(PDT) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 표준 PDT
• 저선량 PDT
• 반량 PDT
• 세계의 맥락막 신생혈관 시장 : 벨테포르핀 나트륨 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 정맥내 투여
• 항 VEGF와의 병용 요법
• 세계의 맥락막 신생혈관 시장 : 라니비주맙 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 월1회 투여
• 필요에 따라 투여
• 치료와 연장의 처방
• 세계의 맥락막 신생혈관 시장 : 베바시주맙 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 적응 외 사용
• 복합 유리체내 주사
• 세계의 맥락막 신생혈관 시장 : 아프리베르셉트 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 고정투여요법
• 치료와 연장의 처방
• 세계의 맥락막 신생혈관 시장 : 페가타니브 나트륨 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 단제요법
• 병용요법

제7장 지역별 및 국가별 분석

• 세계의 맥락막 신생혈관 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 맥락막 신생혈관 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 맥락막 신생혈관 시장 : 경쟁 구도
• 맥락막 신생혈관 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Roche Holding AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bayer Aktiengesellschaft 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Teva Pharmaceutical Industries Limited
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• Alcon Inc.
• Genentech Inc.
• Bausch Lomb Incorporated
• Samsung Bioepis Co. Ltd.
• Santen Pharmaceutical Co. Ltd.
• Apellis Pharmaceuticals Inc.
• Kodiak Sciences Inc.
• Xbrane Biopharma AB
• Allergan Inc.
• Adverum Biotechnologies Inc.

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 맥락막 신생혈관 시장(2029년) : 새로운 기회를 제공하는 국가
• 맥락막 신생혈관 시장(2029년) : 새로운 기회를 제공하는 부문
• 맥락막 신생혈관 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage retinal tissues and lead to vision distortion or loss.

The main treatment options for choroidal neovascularization include anti-angiogenic therapy, laser photocoagulation, photodynamic therapy, verteporfin sodium, ranibizumab, bevacizumab, aflibercept, and pegaptanib sodium. Anti-angiogenic therapy works by inhibiting the formation of new blood vessels (angiogenesis), helping to prevent the growth of abnormal blood vessels. These treatments are commonly used for specific conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), myopic macular degeneration (MMD), and other related conditions. The administration route may vary, including intravitreal, subconjunctival, periocular, or oral methods. These therapies are primarily administered in hospitals, ophthalmology clinics, and ambulatory surgical centers.

The choroidal neovascularization market research report is one of a series of new reports from The Business Research Company that provides choroidal neovascularization market statistics, including the choroidal neovascularization industry global market size, regional shares, competitors with the choroidal neovascularization market share, detailed choroidal neovascularization market segments, market trends, and opportunities, and any further data you may need to thrive in the choroidal neovascularization industry. This choroidal neovascularization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The choroidal neovascularization market size has grown strongly in recent years. It will grow from $3.37 billion in 2024 to $3.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of sedentary lifestyle diseases, the rising incidence of age-related macular degeneration, a higher occurrence of retinal illnesses, a growing elderly population, escalating eye care costs, and expanding education and screening initiatives.

The choroidal neovascularization market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth during the forecast period can be attributed to factors such as increasing patient awareness, the growing adoption of optical coherence tomography angiography, rising demand for minimally invasive procedures, favorable reimbursement policies, and a growing geriatric population. Key trends in this period include the emergence of intravitreal anti-vascular endothelial growth factor (VEGF) therapies, new gene treatments, gene therapy approaches, the adoption of telemedicine, the development of combination therapies, and personalized treatment strategies.

The increasing prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the choroidal neovascularization (CNV) market in the future. AMD is an eye condition that gradually damages the macula, resulting in central vision loss, particularly among older adults. The rising prevalence of AMD is attributed to factors such as an aging population, increased life expectancy, lifestyle changes, genetic influences, and increased exposure to environmental risks. CNV plays a significant role in wet AMD, where abnormal blood vessel growth beneath the retina leads to vision deterioration. Advanced treatments such as anti-VEGF therapy are used to manage CNV, slow the progression of AMD, and help preserve central vision in affected individuals. For example, in September 2022, the National Institutes of Health projected that by 2040, AMD cases may reach 300 million, and by 2050, 5.4 million Americans could be affected. Therefore, the rising prevalence of AMD is driving the growth of the CNV market.

Leading companies in the CNV market are focusing on developing innovative treatments, such as photodynamic therapy (PDT), to provide eye care professionals with more precise and effective options that enhance patient outcomes and treatment delivery. PDT uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the approval of the ML6710i photodynamic laser by the U.S. Food and Drug Administration. This therapy is used in conjunction with Bausch + Lomb's VISUDYNE therapy to treat CNV caused by AMD. The advanced, mobile ophthalmic laser offers a targeted approach to treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.

In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired the CIMERLI business from Coherus for $170 million. With this acquisition, Sandoz aims to expand its portfolio in the ophthalmic sector, strengthening its ability to offer innovative treatments for retinal diseases, such as AMD. Coherus BioSciences, a U.S.-based biopharmaceutical company, focuses on the research and development of treatments for diseases such as CNV.

Major players in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in choroidal neovascularization report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the choroidal neovascularization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The choroidal neovascularization market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The choroidal neovascularization market also includes sales of injections, therapy agents, and surgical & laser devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Choroidal Neovascularization Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on choroidal neovascularization market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for choroidal neovascularization ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The choroidal neovascularization market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
• 2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications
• 3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral
• 4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers
• Subsegments:
• 1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
• 2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy
• 3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT
• 4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF
• 5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen
• 6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections
• 7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen
• 8) By Pegaptanib Sodium: Monotherapy; Combination Therapy
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; Bayer Aktiengesellschaft; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Choroidal Neovascularization Market Characteristics

3. Choroidal Neovascularization Market Trends And Strategies

4. Choroidal Neovascularization Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Choroidal Neovascularization Growth Analysis And Strategic Analysis Framework

• 5.1. Global Choroidal Neovascularization PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Choroidal Neovascularization Market Growth Rate Analysis
• 5.4. Global Choroidal Neovascularization Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Choroidal Neovascularization Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Choroidal Neovascularization Total Addressable Market (TAM)

6. Choroidal Neovascularization Market Segmentation

• 6.1. Global Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Angiogenic Therapy
• Laser Photocoagulation
• Photodynamic Therapy
• Verteporfin Sodium
• Ranibizumab
• Bevacizumab
• Aflibercept
• Pegaptanib Sodium
• 6.2. Global Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Age-Related Macular Degeneration (AMD)
• Diabetic Macular Edema (DME)
• Central Serous Chorioretinopathy (CSC)
• Polypoidal Choroidal Vasculopathy (PCV)
• Myopic Macular Degeneration (MMD)
• Other Indications
• 6.3. Global Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravitreal
• Subconjunctival
• Periocular
• Oral
• 6.4. Global Choroidal Neovascularization Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers
• Research Centers
• 6.5. Global Choroidal Neovascularization Market, Sub-Segmentation Of Anti-Angiogenic Therapy (Anti-VEGF Therapy), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranibizumab
• Bevacizumab
• Aflibercept
• Pegaptanib Sodium
• 6.6. Global Choroidal Neovascularization Market, Sub-Segmentation Of Laser Photocoagulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thermal Laser Photocoagulation
• MicroPulse Laser Therapy
• 6.7. Global Choroidal Neovascularization Market, Sub-Segmentation Of Photodynamic Therapy (PDT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard PDT
• Low-Fluence PDT
• Half-Dose PDT
• 6.8. Global Choroidal Neovascularization Market, Sub-Segmentation Of Verteporfin Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Administration
• Combination Therapy With Anti-VEGF
• 6.9. Global Choroidal Neovascularization Market, Sub-Segmentation Of Ranibizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monthly Dosing
• As-Needed Dosing
• Treat-and-Extend Regimen
• 6.10. Global Choroidal Neovascularization Market, Sub-Segmentation Of Bevacizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Off-Label Use
• Compounded Intravitreal Injections
• 6.11. Global Choroidal Neovascularization Market, Sub-Segmentation Of Aflibercept, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fixed-Dosing Regimen
• Treat-and-Extend Regimen
• 6.12. Global Choroidal Neovascularization Market, Sub-Segmentation Of Pegaptanib Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy

7. Choroidal Neovascularization Market Regional And Country Analysis

• 7.1. Global Choroidal Neovascularization Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Choroidal Neovascularization Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Choroidal Neovascularization Market

• 8.1. Asia-Pacific Choroidal Neovascularization Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Choroidal Neovascularization Market

• 9.1. China Choroidal Neovascularization Market Overview
• 9.2. China Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Choroidal Neovascularization Market

• 10.1. India Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Choroidal Neovascularization Market

• 11.1. Japan Choroidal Neovascularization Market Overview
• 11.2. Japan Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Choroidal Neovascularization Market

• 12.1. Australia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Choroidal Neovascularization Market

• 13.1. Indonesia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Choroidal Neovascularization Market

• 14.1. South Korea Choroidal Neovascularization Market Overview
• 14.2. South Korea Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Choroidal Neovascularization Market

• 15.1. Western Europe Choroidal Neovascularization Market Overview
• 15.2. Western Europe Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Choroidal Neovascularization Market

• 16.1. UK Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Choroidal Neovascularization Market

• 17.1. Germany Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Choroidal Neovascularization Market

• 18.1. France Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Choroidal Neovascularization Market

• 19.1. Italy Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Choroidal Neovascularization Market

• 20.1. Spain Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Choroidal Neovascularization Market

• 21.1. Eastern Europe Choroidal Neovascularization Market Overview
• 21.2. Eastern Europe Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Choroidal Neovascularization Market

• 22.1. Russia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Choroidal Neovascularization Market

• 23.1. North America Choroidal Neovascularization Market Overview
• 23.2. North America Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Choroidal Neovascularization Market

• 24.1. USA Choroidal Neovascularization Market Overview
• 24.2. USA Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Choroidal Neovascularization Market

• 25.1. Canada Choroidal Neovascularization Market Overview
• 25.2. Canada Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Choroidal Neovascularization Market

• 26.1. South America Choroidal Neovascularization Market Overview
• 26.2. South America Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Choroidal Neovascularization Market

• 27.1. Brazil Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Choroidal Neovascularization Market

• 28.1. Middle East Choroidal Neovascularization Market Overview
• 28.2. Middle East Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Choroidal Neovascularization Market

• 29.1. Africa Choroidal Neovascularization Market Overview
• 29.2. Africa Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Choroidal Neovascularization Market Competitive Landscape And Company Profiles

• 30.1. Choroidal Neovascularization Market Competitive Landscape
• 30.2. Choroidal Neovascularization Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Choroidal Neovascularization Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Limited
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Astellas Pharma Inc.
• 31.4. Biogen Inc.
• 31.5. Chugai Pharmaceutical Co. Ltd.
• 31.6. Alcon Inc.
• 31.7. Genentech Inc.
• 31.8. Bausch + Lomb Incorporated
• 31.9. Samsung Bioepis Co. Ltd.
• 31.10. Santen Pharmaceutical Co. Ltd.
• 31.11. Apellis Pharmaceuticals Inc.
• 31.12. Kodiak Sciences Inc.
• 31.13. Xbrane Biopharma AB
• 31.14. Allergan Inc.
• 31.15. Adverum Biotechnologies Inc.

32. Global Choroidal Neovascularization Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Choroidal Neovascularization Market

34. Recent Developments In The Choroidal Neovascularization Market

35. Choroidal Neovascularization Market High Potential Countries, Segments and Strategies

• 35.1 Choroidal Neovascularization Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Choroidal Neovascularization Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Choroidal Neovascularization Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료